Distributor inventory | Tablet
Sitagliptin 50 mg + Metformin hydrochloride 1000 mg (extended-release) tablet
Type 2 diabetes mellitus: to improve blood glucose control in adults when diet and exercise alone are not sufficient; used as combination therapy (often when metformin alone is inadequate).
Sitagliptin is a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin release and reducing glucagon. Metformin reduces hepatic glucose production and improves insulin sensitivity; the ER form provides prolonged release to help reduce GI side effects.
Oral tablet (extended-release). Take exactly as prescribed, usually once daily with the evening meal; swallow whole without crushing/chewing/breaking. Take with food to reduce stomach upset; maintain diet/exercise and monitor blood glucose.
Common side effects of SITA M ER 50/1000 TAB may include:
Type 2 diabetes only (not for type 1 diabetes or diabetic ketoacidosis). Risk of lactic acidosis with metformin—avoid in severe kidney impairment; assess eGFR before and during therapy. Temporarily stop metformin around iodinated contrast studies or major surgery as advised. Use caution with liver disease, dehydration, heavy alcohol use, heart failure, and in elderly. Sitagliptin may rarely cause pancreatitis or severe joint pain; seek medical help for severe abdominal pain. Watch for hypoglycemia when used with insulin or sulfonylureas. Vitamin B12 deficiency may occur with long-term metformin use.
